Amoxillin- and pefloxacin-induced cholesterogenesis and phospholipidosis in rat tissues
Autor: | Solomon O. Rotimi, Elizabeth A. Balogun, Regina Ngozi Ugbaja, D.A. Ojo, Oladipo Ademuyiwa, Olusola A Talabi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
Male
medicine.medical_specialty Erythrocytes medicine.drug_class Endocrinology Diabetes and Metabolism Clinical Biochemistry Antibiotics Cholesterogenesis Biology Kidney Pefloxacin Phospholipidosis chemistry.chemical_compound Endocrinology Internal medicine medicine Amoxillin Animals Lung Phospholipids Biochemistry medical Brain Chemistry Cholesterol Research Myocardium Biochemistry (medical) Amoxicillin Lipid metabolism medicine.disease Anti-Bacterial Agents Rats medicine.anatomical_structure chemistry Dyslipidemia Liver lipids (amino acids peptides and proteins) Acyl Coenzyme A Spleen Lipoprotein medicine.drug |
Zdroj: | Lipids in Health and Disease |
ISSN: | 1476-511X |
Popis: | Background To investigate whether amoxillin and pefloxacin perturb lipid metabolism. Methods Rats were treated with therapeutic doses of each antibiotic for 5 and 10 days respectively. Twenty four hours after the last antibiotic treatment and 5 days after antibiotic withdrawal, blood and other tissues (liver, kidney, brain, heart and spleen) were removed from the animals after an overnight fast and analysed for their lipid contents. Results Both antibiotics produced various degrees of compartment-specific dyslipidemia in the animals. While plasma and erythrocyte dyslipidemia was characterised by up-regulation of the concentrations of the major lipids (cholesterol, triglycerides, phospholipids and free fatty acids), hepatic and renal dyslipidemia was characterised by cholesterogenesis and phospholipidosis. Splenic dyslipidemia was characterised by cholesterogenesis and decreased phospholipid levels. Cardiac and brain cholesterol contents were not affected by the antibiotics. A transient phospholipidosis was observed in the brain whereas cardiac phospholipids decreased significantly. Lipoprotein abnormalities were reflected as down-regulation of HDL cholesterol. Furthermore, the two antibiotics increased the activity of hepatic HMG-CoA reductase. Although erythrocyte phospholipidosis was resolved 5 days after withdrawing the antibiotics, dyslipidemia observed in other compartments was still not reversible. Conclusion Our findings suggest that induction of cholesterogenesis and phospholipidosis might represent additional adverse effects of amoxillin and pefloxacin. |
Databáze: | OpenAIRE |
Externí odkaz: |